RecruitingPHASE1, PHASE2NCT01306019
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Studying T-B+ severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Suk S De Ravin, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 2-50 years · MALE
- Timeline
- 2012 – 2032
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01306019 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06851767Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE2NCT03619551Conditioning SCID Infants Diagnosed EarlyCenter for International Blood and Marrow Transplant Research